Deciphering NASH-HCC development and response to therapy

Chairs: 

• Helen Reeves, Professor of Liver Cancer in the Northern Institute for Cancer Research,  UK
• Josep Maria Llovet, Founder and Director of the Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School of Medicine, New York University (USA), and Professor of Research-ICREA in the BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic, University of Barcelona, Spain.

Speakers: 

• Current oncology therapies and NASH-HCC, Andrea Casadei-Gardini, Head of Liver cancer division at the Oncology unit of the San Raffaele Research Hospital and Senior researcher at the Vita-Salute San Raffaele University, Milan, Italy 
• The immune environment in NASH-HCC , Derek Mann, Professor of Hepatology, Newcastle Fibrosis Research Group, UK